ACTIVITIES OF THE TRIAZOLE D0870 INVITRO AND AGAINST MURINE BLASTOMYCOSIS

The novel triazole D0870 was tested for in vitro activity as well as i n vivo in a murine model of pulmonary blastomycosis. In vitro, D0870 h ad inhibitory and fungicidal activity against Blastomyces dermatitidis (MIC = 0.048 mug/ml; minimal fungicidal concentration = (0.097 mug/ml ). In vivo, D0870 was approximately 100-fold more active than fluconaz ole on the basis of milligrams per kilogram of body weight given once daily (QD) against blastomycosis. D0870 doses of both 1 or 10 mg/kg gi ven QD and 10 or 100 mg/kg given every other day prolonged survival (P < 0.001) over fluconazole (100 mg/kg given QD). A D0870 dosage of 1 m g/kg QD was equivalent to fluconazole given at 100 mg/kg in reduction of lung burdens of B. dermatitidis, and D0870 administered at 10 mg/kg QD and 10 or 100 mg/kg every other day caused greater reduction (P < 0.001). However, D0870 at 100 mg/kg given QD was lethally toxic, where as fluconazole at 100 mg/kg was not. These results indicate that D0870 is an effective therapy for murine blastomycosis and should be furthe r tested.